Which has stronger earnings and valuation, ACET or KTTA?

Adicet Bio is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adicet Bio N/A N/A -$116.80M -$11.45 N/A Pasithea Therapeutics N/A N/A -$20.43M -$1.58 N/A

Is ACET or KTTA more profitable?

Pasithea Therapeutics' return on equity of -49.49% beat Adicet Bio's return on equity. Company Net Margins Return on Equity Return on Assets Adicet Bio N/A -74.90% -60.87% Pasithea Therapeutics N/A -49.49% -46.81%

Do analysts rate KTTA or KVAC?

Pasithea Therapeutics currently has a consensus price target of $3.00, indicating a potential upside of 571.14%. Given Pasithea Therapeutics' higher possible upside, equities research analysts plainly believe Pasithea Therapeutics is more favorable than Keen Vision Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pasithea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Keen Vision Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, KTTA or KVAC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pasithea Therapeutics N/A N/A -$20.43M -$1.58 N/A Keen Vision Acquisition N/A N/A N/A N/A N/A

Is KTTA or KVAC more profitable?

Keen Vision Acquisition's return on equity of 0.00% beat Pasithea Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pasithea Therapeutics N/A -49.49% -46.81% Keen Vision Acquisition N/A N/A N/A

Which has higher earnings & valuation, KTTA or INKT?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pasithea Therapeutics N/A N/A -$20.43M -$1.58 N/A MiNK Therapeutics N/A N/A -$12.49M -$2.40 N/A

Is KTTA or INKT more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Pasithea Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pasithea Therapeutics N/A -49.49% -46.81% MiNK Therapeutics N/A N/A -92.37%

Is KTTA or CNTB more profitable?

Pasithea Therapeutics' return on equity of -49.49% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Pasithea Therapeutics N/A -49.49% -46.81% Connect Biopharma N/A -165.41% -121.58%

Pasithea Therapeutics (KTTA) Competitors

$0.46 +0.01 (+2.68%)

As of 02:24 PM Eastern

Compare

KTTA vs. YARW, ACET, KVAC, INKT, and CNTB

Should you buy Pasithea Therapeutics stock or one of its competitors? Pasithea Therapeutics's main competitors and comparable companies include Yarrow Bioscience (YARW), Adicet Bio (ACET), Keen Vision Acquisition (KVAC), MiNK Therapeutics (INKT), and Connect Biopharma (CNTB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Pasithea Therapeutics compare to Yarrow Bioscience?

Pasithea Therapeutics (NASDAQ:KTTA) and Yarrow Bioscience (NASDAQ:YARW) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 83.8% of Yarrow Bioscience shares are held by institutional investors. 1.5% of Pasithea Therapeutics shares are held by company insiders. Comparatively, 3.0% of Yarrow Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Pasithea Therapeutics has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Pasithea Therapeutics' return on equity of -49.49% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-49.49%	-46.81%
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%

Pasithea Therapeutics has higher earnings, but lower revenue than Yarrow Bioscience. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$1.58	N/A
Yarrow Bioscience	$570K	87.74	-$26.48M	-$14.64	N/A

Pasithea Therapeutics has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Yarrow Bioscience has a beta of 2.02, meaning that its stock price is 102% more volatile than the broader market.

In the previous week, Pasithea Therapeutics' average media sentiment score of 0.00 equaled Yarrow Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Pasithea Therapeutics	Neutral
Yarrow Bioscience	Neutral

Pasithea Therapeutics presently has a consensus price target of $3.00, suggesting a potential upside of 571.14%. Yarrow Bioscience has a consensus price target of $58.00, suggesting a potential upside of 209.66%. Given Pasithea Therapeutics' higher possible upside, equities analysts clearly believe Pasithea Therapeutics is more favorable than Yarrow Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Yarrow Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Pasithea Therapeutics beats Yarrow Bioscience on 7 of the 13 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Adicet Bio?

Adicet Bio (NASDAQ:ACET) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Adicet Bio has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

83.9% of Adicet Bio shares are held by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are held by institutional investors. 3.4% of Adicet Bio shares are held by insiders. Comparatively, 1.5% of Pasithea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Pasithea Therapeutics' return on equity of -49.49% beat Adicet Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adicet Bio	N/A	-74.90%	-60.87%
Pasithea Therapeutics	N/A	-49.49%	-46.81%

Adicet Bio presently has a consensus target price of $37.80, suggesting a potential upside of 504.80%. Pasithea Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 571.14%. Given Pasithea Therapeutics' higher probable upside, analysts plainly believe Pasithea Therapeutics is more favorable than Adicet Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adicet Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Adicet Bio is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adicet Bio	N/A	N/A	-$116.80M	-$11.45	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$1.58	N/A

In the previous week, Adicet Bio had 2 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 2 mentions for Adicet Bio and 0 mentions for Pasithea Therapeutics. Adicet Bio's average media sentiment score of 0.61 beat Pasithea Therapeutics' score of 0.00 indicating that Adicet Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Adicet Bio	Positive
Pasithea Therapeutics	Neutral

Summary

Adicet Bio beats Pasithea Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Keen Vision Acquisition?

Pasithea Therapeutics (NASDAQ:KTTA) and Keen Vision Acquisition (NASDAQ:KVAC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

In the previous week, Pasithea Therapeutics' average media sentiment score of 0.00 equaled Keen Vision Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Pasithea Therapeutics	Neutral
Keen Vision Acquisition	Neutral

Pasithea Therapeutics has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, Keen Vision Acquisition has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$1.58	N/A
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A

Pasithea Therapeutics currently has a consensus price target of $3.00, indicating a potential upside of 571.14%. Given Pasithea Therapeutics' higher possible upside, equities research analysts plainly believe Pasithea Therapeutics is more favorable than Keen Vision Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Keen Vision Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Keen Vision Acquisition's return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-49.49%	-46.81%
Keen Vision Acquisition	N/A	N/A	N/A

23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 51.7% of Keen Vision Acquisition shares are held by institutional investors. 1.5% of Pasithea Therapeutics shares are held by company insiders. Comparatively, 80.2% of Keen Vision Acquisition shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Keen Vision Acquisition beats Pasithea Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Pasithea Therapeutics compare to MiNK Therapeutics?

Pasithea Therapeutics (NASDAQ:KTTA) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$1.58	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A

23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 1.5% of Pasithea Therapeutics shares are owned by company insiders. Comparatively, 20.4% of MiNK Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

MiNK Therapeutics' return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-49.49%	-46.81%
MiNK Therapeutics	N/A	N/A	-92.37%

In the previous week, MiNK Therapeutics had 6 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 6 mentions for MiNK Therapeutics and 0 mentions for Pasithea Therapeutics. MiNK Therapeutics' average media sentiment score of 0.45 beat Pasithea Therapeutics' score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Pasithea Therapeutics	Neutral
MiNK Therapeutics	Neutral

Pasithea Therapeutics currently has a consensus target price of $3.00, suggesting a potential upside of 571.14%. MiNK Therapeutics has a consensus target price of $35.00, suggesting a potential upside of 199.15%. Given Pasithea Therapeutics' higher possible upside, equities research analysts clearly believe Pasithea Therapeutics is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Pasithea Therapeutics has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

Summary

MiNK Therapeutics beats Pasithea Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Connect Biopharma?

Pasithea Therapeutics (NASDAQ:KTTA) and Connect Biopharma (NASDAQ:CNTB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Pasithea Therapeutics' return on equity of -49.49% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-49.49%	-46.81%
Connect Biopharma	N/A	-165.41%	-121.58%

Pasithea Therapeutics has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.16, suggesting that its share price is 116% less volatile than the broader market.

Pasithea Therapeutics has higher earnings, but lower revenue than Connect Biopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$1.58	N/A
Connect Biopharma	$60K	950.22	-$55.48M	-$1.19	N/A

Pasithea Therapeutics currently has a consensus target price of $3.00, suggesting a potential upside of 571.14%. Connect Biopharma has a consensus target price of $6.14, suggesting a potential upside of 578.47%. Given Connect Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Connect Biopharma is more favorable than Pasithea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Connect Biopharma had 27 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 27 mentions for Connect Biopharma and 0 mentions for Pasithea Therapeutics. Connect Biopharma's average media sentiment score of 0.13 beat Pasithea Therapeutics' score of 0.00 indicating that Connect Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Pasithea Therapeutics	Neutral
Connect Biopharma	Neutral

23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 1.5% of Pasithea Therapeutics shares are held by company insiders. Comparatively, 22.6% of Connect Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Connect Biopharma beats Pasithea Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Pasithea Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KTTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KTTA vs. The Competition

Export

Metric	Pasithea Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.34M	$3.87B	$7.22B	$13.36B
Dividend Yield	N/A	3.65%	2.53%	17.39%
P/E Ratio	-0.29	13.63	275.20	26.19
Price / Sales	N/A	1,235.41	635.24	106.81
Price / Cash	N/A	126.56	79.41	53.24
Price / Book	0.19	16.04	10.78	6.30
Net Income	-$20.43M	-$22.68M	$3.50B	$382.16M
7 Day Performance	-6.90%	-4.31%	-1.23%	-0.74%
1 Month Performance	-20.86%	-12.35%	-6.33%	-5.18%
1 Year Performance	-44.36%	13.56%	6.05%	0.86%

Pasithea Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KTTA Pasithea Therapeutics	2.9757 of 5 stars	$0.46 +2.7%	$3.00 +553.6%	-45.7%	$15.34M	N/A	N/A	5
YARW Yarrow Bioscience	2.3988 of 5 stars	$22.52 -6.9%	$58.00 +157.5%	N/A	$64.58M	$570K	N/A	30
ACET Adicet Bio	3.8951 of 5 stars	$7.14 +4.5%	$37.80 +429.4%	-60.9%	$63.94M	N/A	N/A	102
KVAC Keen Vision Acquisition	N/A	$11.51 flat	N/A	N/A	$63.37M	N/A	N/A	N/A
INKT MiNK Therapeutics	2.7784 of 5 stars	$12.55 +2.4%	$35.00 +178.9%	-23.0%	$62.56M	N/A	N/A	15	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KTTA) was last updated on 10/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pasithea Therapeutics (KTTA) Competitors

KTTA vs. YARW, ACET, KVAC, INKT, and CNTB

How does Pasithea Therapeutics compare to Yarrow Bioscience?

Summary

How does Pasithea Therapeutics compare to Adicet Bio?

Summary

How does Pasithea Therapeutics compare to Keen Vision Acquisition?

Summary

How does Pasithea Therapeutics compare to MiNK Therapeutics?

Summary

How does Pasithea Therapeutics compare to Connect Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KTTA vs. The Competition

Pasithea Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pasithea Therapeutics (KTTA) Competitors

KTTA vs. YARW, ACET, KVAC, INKT, and CNTB

How does Pasithea Therapeutics compare to Yarrow Bioscience?

Do insiders & institutionals believe in KTTA or YARW?

Is KTTA or YARW more profitable?

Which has higher earnings & valuation, KTTA or YARW?

Which has more risk and volatility, KTTA or YARW?

Does the media prefer KTTA or YARW?

Do analysts recommend KTTA or YARW?

Summary

How does Pasithea Therapeutics compare to Adicet Bio?

Which has more risk and volatility, ACET or KTTA?

Do insiders and institutionals hold more shares of ACET or KTTA?

Is ACET or KTTA more profitable?

Do analysts prefer ACET or KTTA?

Which has stronger earnings and valuation, ACET or KTTA?

Does the media favor ACET or KTTA?

Summary

How does Pasithea Therapeutics compare to Keen Vision Acquisition?

Does the media refer more to KTTA or KVAC?

Which has more risk & volatility, KTTA or KVAC?

Which has better valuation & earnings, KTTA or KVAC?

Do analysts rate KTTA or KVAC?

Is KTTA or KVAC more profitable?

Do institutionals and insiders believe in KTTA or KVAC?

Summary

How does Pasithea Therapeutics compare to MiNK Therapeutics?

Which has higher earnings & valuation, KTTA or INKT?

Do insiders & institutionals hold more shares of KTTA or INKT?

Is KTTA or INKT more profitable?

Does the media prefer KTTA or INKT?

Do analysts recommend KTTA or INKT?

Which has more risk and volatility, KTTA or INKT?

Summary

How does Pasithea Therapeutics compare to Connect Biopharma?

Is KTTA or CNTB more profitable?

Which has more volatility and risk, KTTA or CNTB?

Which has stronger earnings & valuation, KTTA or CNTB?

Do analysts rate KTTA or CNTB?

Does the media prefer KTTA or CNTB?

Do insiders & institutionals hold more shares of KTTA or CNTB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KTTA vs. The Competition

Pasithea Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools